Section 2 – Product/Company Update Remote Pharmacy announces continued nationwide availability of its compounded GLP-1 ...

The 35-year-old mom is one of many patients taking a compounded version of tirzepatide produced by a pharmacy while Eli Lilly's brand-name versions, Zepbound and Mounjaro, have been in short supply.

If tirzepatide remains off the FDA's drug shortage list, compounding pharmacies must cease the production of these medications on any significant scale, according to gastroenterologist and obesity ...

Shortages of tirzepatide, sold as a diabetes drug and a weight-loss medication , have fueled demand for compounding pharmacies to make their own versions of the medicine, which patients say are ...

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from Mounjaro. The Food and Drug Administration (FDA) does not regulate the ...

New rules may limit the supply of compounded GLP-1 weight loss drugs — less expensive copies of Ozempic, Wegovy, Mounjaro, and Zepbound — but not every product is being pulled off the shelves.

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

Discover the top 25 most expensive drugs in the U.S., including the 100% increase in Ozempic and Wegovy spending, and the 373% surge in Mounjaro's popularity.

Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month ...